Johnson & Johnson (NYSE: JNJ), together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and others; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Company Overview
- Market Cap: 397.483 Billion
- PE Ratio: 27.34
- EPS: 6.04
- Dividend Yield: 3.00 %
Johnson & Johnson is a healthcare leader that has been rewarding shareholders for a long time. The pharmaceutical company is also a Dividend King, having raised its payouts for 62 consecutive years. The business delivers consistent financial results. In the third quarter, net sales grew by 5.2% yearly to $22.5 billion. Johnson & Johnson’s portfolio features growth drivers such as cancer medicines Darzalex and Erleada, despite the decelerating sales of some of its older drugs. The company’s medical devices unit makes the business more diversified.
J&J has a deep pipeline with dozens of ongoing programs. The company generally records at least a few clinical or regulatory wins every quarter. During the third quarter, it earned label expansions for Rybrevant in treating second-line advanced lung cancer and Tremfya for moderately to severe active ulcerative colitis.
Furthermore, Johnson & Johnson boasts a higher credit rating than the U.S. government, which is strong evidence of its rock-solid balance sheet. Johnson & Johnson’s forward yield is around 3%, and its cash payout ratio is over 58%.
Therefore, JNJ is one of the best reliable dividend growth stocks to own as a long-term investment.